NEW YORK, September 22, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Infinity Pharmaceuticals, Inc. (NASDAQ:
INFI), Boston Scientific Corporation (NYSE: BSX), Johnson
& Johnson (NYSE: JNJ), Mallinckrodt plc (NYSE: MNK), Eli Lilly and
Company (NYSE: LLY). On Monday,
September 21, 2015, NASDAQ ended at 4,828.95, up 0.04%, Dow
Jones advanced 0.77%, to finish the day at 16,510.19, and the
S&P closed at 1,966.97, up 0.46%. Register for your
complimentary reports at the links given below.
Infinity Pharmaceuticals Inc
--
Infinity Pharmaceuticals Inc.'s stock edged higher by 8.62% to
close Monday's session at USD 9.96.
The company's shares oscillated between USD
9.63 and USD 10.76 in trade during the day. The stock
recorded a trading volume of 2.39 million shares, which was above
its 50-day daily average volume of 0.71 million shares and above
its 52-week average volume of 0.68 million shares. Over the last
three days, Infinity Pharmaceuticals Inc.'s shares have advanced
13.57% and in the past one week it has moved up 12.42%.
Furthermore, over the last three months, the stock has lost 14.58%
and in the past six months, the shares have shed 33.24%. On a
compounded total return basis, the stock yielded a return of 5.51%
in the past one month. The stock is at a price to book ratio of
5.61, which compares to a historical PB ratio close to 3.94.
Additionally, the stock is trading at a price to sales ratio of
2.81. Sign up and read the free notes on INFI at:
http://www.aciassociation.com/INFI.pdf
--
Boston Scientific Corp
--
The stock of Boston Scientific Corp lost 0.18% to close Monday's
session at USD 16.72. The shares of
the company moved in the range of USD
16.55 and USD 16.96. A trading
volume of 8.37 million shares was recorded, which was lower than
its 150-day daily average volume of 10.03 million shares and below
its 52-week average volume of 10.99 million shares. Over the last
five days, Boston Scientific Corp's shares have declined by 0.06%.
Additionally, in the past six months, the shares have registered a
loss of 7.01%. The stock yielded a positive return of 2.26% in the
past one month, while generating negative return of 6.28% in the
last three months, on a compounded total return basis. Further, the
stock is trading at a price to earnings ratio of 98.35 and a price
to book ratio of 3.41. Register for free on ACI Association and
access the latest research on BSX at:
http://www.aciassociation.com/BSX.pdf
--
JOHNSON & JOHNSON
--
JOHNSON & JOHNSON's stock decreased by 0.28% to close
Monday's session at USD 93.13. The
company's shares fluctuated in the range of USD 92.37 and USD
94.60 in trade during the day. A total of 7.05 million
shares exchanged hands, which was lesser than its 50-day daily
average volume of 8.59 million shares and was below its 52-week
average volume of 8.35 million shares. Over the last three days
JOHNSON & JOHNSON's shares have declined by 1.56% and in the
past one week it has moved down 0.20%. Furthermore, over the last
three months, the stock has lost 6.95% and in the past six months,
the shares have shed 9.57%. JOHNSON & JOHNSON has a current
dividend yield of 3.21%. Further, the company is trading at a price
to earnings ratio of 16.37 and a price to book ratio of 3.63. The
complete research on JNJ is available for free at:
http://www.aciassociation.com/JNJ.pdf
--
Mallinckrodt plc
--
Mallinckrodt plc's stock slipped by
10.02% to close Monday's session at USD
73.87. The company's shares oscillated between USD 72.81 and USD 81.75 marking a new 52-week low
during the session. The stock recorded a trading volume of 6.82
million shares, which was above its 50-day daily average volume of
1.95 million shares and above its 52-week average volume of 1.49
million shares. Over the last three days, Mallinckrodt plc's shares have declined by 11.65%
and in the past week, it has lost 9.57%. In addition, over the last
three months, the stock has lost 40.44% and year to date, the
shares have shed 25.41%. The stock has generated negative returns
of 16.34% in the past one month, and 16.95% in the past one year,
on a compounded total return basis. Free in-depth research on MNK
is available at: http://www.aciassociation.com/MNK.pdf
--
Eli Lilly and Co
--
Eli Lilly and Co's stock declined 1.02% to close Monday's
session at USD 87.59. The share price
vacillated between USD 87.11 and USD
89.81 in trade during the day. The stock recorded a trading
volume of 6.64 million shares, which was above its 50-day daily
average volume of 5.00 million shares and above its 52-week average
volume of 4.76 million shares. Over the last three days Eli Lilly
and Co's shares have advanced 3.72% and in the past one week it has
moved up 6.96%. On a compounded total return basis, the company has
returned 16.55% in the last half a year, and 36.20% in the past one
year. Further, the company is trading at a price to earnings ratio
of 45.47 and a price to book ratio of 6.63. Additionally, the stock
is trading at a price to cash flow ratio of 26.91 and price to
sales ratio of 4.95. The complimentary notes on LLY can be
downloaded in PDF format at:
http://www.aciassociation.com/LLY.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com